Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Authors:
Open Access
- 2 November 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Abstract
To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy. A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change. All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (< 33 mL) and large (≥ 33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥ 13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (< 33 mL), patients with lesser testosterone reduction (< Δ400 ng/dL) showed greater improvement in IPSS-ss by 7.5% compared with those with greater testosterone reduction (≥ Δ400 ng/dL). In conclusion, although androgen deprivation therapy generally improves lower urinary tract symptoms, it may worsen specifically storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients.Keywords
All Related Versions
Funding Information
- Hallym University (HURF-2020-10)
This publication has 25 references indexed in Scilit:
- Analysis of Initial Baseline Clinical Parameters and Treatment Strategy Associated with Medication Failure in the Treatment of Benign Prostatic Hyperplasia in KoreaInternational Neurourology Journal, 2010
- Lower urinary-tract symptoms and testosterone in elderly menWorld Journal of Urology, 2008
- Androgens and bladder outlet obstruction: a correlation with pressure‐flow variables in a preliminary studyBJU International, 2008
- A Dose‐Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone UndecanoateJournal of Andrology, 2008
- An investigation of the relationship between sex‐steroid levels and urological symptoms: results from the Boston Area Community Health surveyBJU International, 2007
- Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population‐based study of 40 000 Swedish menBJU International, 2004
- Prostate Volume Reduction With Androgen Deprivation Therapy Before Interstitial BrachytherapyJournal of Urology, 2002
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbitNeurourology and Urodynamics, 1995
- Transurethral Catheter Removal after Bilateral Orchiectomy for Prostatic Carcinoma Associated with Acute Urinary RetentionScandinavian Journal of Urology and Nephrology, 1994